No significant difference in incidence of infections, cancer, renal failure, or severe hypoglycemia… In patients with type 2 diabetes and cardiovascular disease, the use of sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used to lower HbA1c levels, is not associated with an increased risk of cardiovascular events, according to …

Combination of insulin, a GLP-1 receptor agonist and an SGLT-2 inhibitor effective, includes DKA risk.

Spouses or live-in partners of people newly diagnosed with diabetes twice as likely to develop diabetes…

Drug shows a significant reduction in HbA1c in patients with type 2 diabetes… A new investigational drug is underway to help with reduction of HbA1c, weight, and improve glycemic control in type 2 diabetes patients. ITCA 650 is an injection-free GLP-1 receptor agonist that provides continuous subcutaneous exenatide for 12 …

Peglispro allows slow insulin absorption, but associated with injection site reaction and increased ALT and triglycerides… Peglispro or pegylated lispro insulin is currently under phase III investigation for both type 1 and type 2 diabetes. The large hydrodynamic size of peglispro allows slow insulin absorption and reduces clearance, resulting in …

Sulfonylureas not associated with increased cardiovascular mortality, myocardial infarction and stroke in a meta-analysis of 47 randomized clinical trials… Sulfonylureas are relatively inexpensive and are important therapeutic agents in type 2 diabetes management. However, they are not widely used due to safety concerns regarding hypoglycemia and weight gain. Furthermore, it …

The two new injectable drugs, alirocumab and evolocumub, have been recommended for FDA approval by the agency’s Endocrinologic and Metabolic Advisory Committee.…

Fixed-dose insulin glargine/lixisenatide improves HbA1c levels in patients with type 2 diabetes…

GLP-1 analog also showed reduction in weight and incidence of hypoglycemia… Dulaglutide (Trulicity) is a glucagon-like peptide analog that is used once weekly to improve blood glucose level. During the open-label, multinational, parallel arm study, researchers compared the safety and efficacy of dulaglutide 0.75mg and 1.5mg to insulin glargine in …

Diabetes subspecialty and primary care clinics showed low control rates of A1C, LDL cholesterol and microalbuminuria, compared with family practice and internal medicine clinics, according to a study. While the rates of HbA1c, LDL-cholesterol and microalbuminuria testing appear to be high in both diabetes subspecialty and primary care clinics, the …